GIP and diabetes mellitus: Furthermore, sRAGE (AUC0–240) showed strong negative correlation with the incretin hormone GLP-1 in individuals with type 2 diabetes, both during OGTT and IIGI at the 75 g dose (Table 3), which could suggest a diabetes specific gastrointestinal component for sRAGE regulation that warrants further investigation.